Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Viva Gold Reports Multiple High-Grade Gold Hits at the Tonopah Gold Project (click to learn more) Xcyte Digital Corp. Signs Agreement to Purchase Assets of Webinar.net (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Bullboard - Stock Discussion Forum Rakovina Therapeutics Inc V.RKV

Alternate Symbol(s):  RKVTF

Rakovina Therapeutics Inc. is a Canada-based biopharmaceutical company. The Company is engaged in advancing cancer therapies based on deoxyribonucleic acid (DNA)-damage response technologies. The Company has a pipeline of DNA-damage response inhibitors to advance one or more drug candidates into human clinical trials and obtain marketing approval for cancer therapeutics. The Company’s research... see more

TSXV:RKV - Post Discussion

Rakovina Therapeutics Inc > Rakovina Therapeutics Granted Patents For Drug Candidates
View:
Post by AwareInvestor on Apr 08, 2021 9:27am

Rakovina Therapeutics Granted Patents For Drug Candidates

Rakovina Therapeutics has received patents as of this morning. Granted by both the European and Canadian patent offices, the patents are for “Tricyclic Inhibitors of Poly(ADP-Ribose) Polymerase”.

The patents that were granted to the company are related to the firms kt-2000 series of drug candidates. The patents cover both the composition of matter as well as the uses of the drug candidates. The k2-2000 series is being studied by the company as a novel series of DNA-damage response inhibitors, which is being targeted as a potential cancer therapy.
Be the first to comment on this post
Rakovina Therapeutics Inc